Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis
CONCLUSION: Compared to hysterectomy, single agent chemotherapy as a first-line treatment costs $74,526 for each additional QALY gained. Given that this cost falls below the accepted $100,000 willingness-to-pay threshold and waitlist limitations within public healthcare systems, these results support the continued use of chemotherapy as standard of care approach for low-risk GTN.PMID:38705127 | DOI:10.1016/j.ygyno.2024.04.014 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 5, 2024 Category: Cancer & Oncology Authors: Cristina Mitric Rashid K Sayyid Neil E Fleshner Nicole J Look Hong Genevieve Bouchard-Fortier Source Type: research
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
CONCLUSION: The combination of avutometinib and defactinib demonstrates promising in vitro and in vivo anti-tumor activity against primary UCS cell lines and xenografts.PMID:38703673 | DOI:10.1016/j.ygyno.2024.04.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 4, 2024 Category: Cancer & Oncology Authors: Cem Demirkiran Michelle Greenman Stefania Bellone Blair McNamara Tobias Max Philipp Hartwich Diego Manavella Levent Mutlu Margherita Zipponi Yang Yang-Hartwich Kevin Yang Elena Ratner Peter E Schwartz Silvia Coma Jonathan Pachter Alessandro D Santin Source Type: research
Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk
CONCLUSIONS: Variation in MI3AG does not change the accuracy of the test for excluding malignancy, while marked changes may be associated with a slightly higher likelihood of surgical intervention. In addition to MIA3G score itself, the MIA3G RCV may be important for clinical management.PMID:38703674 | DOI:10.1016/j.ygyno.2024.04.020 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 4, 2024 Category: Cancer & Oncology Authors: Todd C Pappas Manjusha Roy Choudhury Balu K Chacko Leo B Twiggs Herbert Fritsche Kevin M Elias Ryan T Phan Source Type: research
Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education
CONCLUSIONS: The experience of GO fellows has shifted toward increased use of MIS. While these trends in care are appropriate, they do not diminish the need in many patients for complex open procedures. These findings should help spur the development of innovative training to maintain the ability to provide these core, specialty-defining procedures safely.PMID:38696840 | DOI:10.1016/j.ygyno.2024.04.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Mitchel Hoffman Victoria Dunsmore William Cliby Dennis Chi Stephanie Wheeler Daniel Clarke-Pearson Source Type: research
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer
CONCLUSIONS: In endometrial cancer, co-mutation of FAT3 and LRP1B not only leads to activation of the immune state, but also represents a subgroup with an improved prognosis, particularly in the MSI-H subtype.PMID:38696842 | DOI:10.1016/j.ygyno.2024.04.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Zhansheng Jiang Mingyu Zhu Lu Zhang Haiyan Cui Richeng Jiang Yanfang Yang Source Type: research
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors
CONCLUSION: Patients with HBOC did not undergo expedited fertility treatment compared to control patients undergoing oocyte and embryo cryopreservation for non-infertility reasons. Patients diagnosed with BRCA1 had more oocytes retrieved compared to the control population which is possibly due to earlier age of presentation in the setting of recommended age of risk reducing surgery being age 35-40. When age matched, cycle outcomes did not differ between HBOC and control patients. Given the known cancer prevention benefit and recommendations for risk-reducing surgery, future studies should focus on guidelines for fertility ...
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Sharonne Holtzman Lily McCarthy Samantha L Estevez Joseph A Lee Morgan F Baird Dmitry Gounko Alan B Copperman Stephanie V Blank Source Type: research
Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education
CONCLUSIONS: The experience of GO fellows has shifted toward increased use of MIS. While these trends in care are appropriate, they do not diminish the need in many patients for complex open procedures. These findings should help spur the development of innovative training to maintain the ability to provide these core, specialty-defining procedures safely.PMID:38696840 | DOI:10.1016/j.ygyno.2024.04.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Mitchel Hoffman Victoria Dunsmore William Cliby Dennis Chi Stephanie Wheeler Daniel Clarke-Pearson Source Type: research
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer
CONCLUSIONS: In endometrial cancer, co-mutation of FAT3 and LRP1B not only leads to activation of the immune state, but also represents a subgroup with an improved prognosis, particularly in the MSI-H subtype.PMID:38696842 | DOI:10.1016/j.ygyno.2024.04.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Zhansheng Jiang Mingyu Zhu Lu Zhang Haiyan Cui Richeng Jiang Yanfang Yang Source Type: research
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors
CONCLUSION: Patients with HBOC did not undergo expedited fertility treatment compared to control patients undergoing oocyte and embryo cryopreservation for non-infertility reasons. Patients diagnosed with BRCA1 had more oocytes retrieved compared to the control population which is possibly due to earlier age of presentation in the setting of recommended age of risk reducing surgery being age 35-40. When age matched, cycle outcomes did not differ between HBOC and control patients. Given the known cancer prevention benefit and recommendations for risk-reducing surgery, future studies should focus on guidelines for fertility ...
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Sharonne Holtzman Lily McCarthy Samantha L Estevez Joseph A Lee Morgan F Baird Dmitry Gounko Alan B Copperman Stephanie V Blank Source Type: research
Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education
CONCLUSIONS: The experience of GO fellows has shifted toward increased use of MIS. While these trends in care are appropriate, they do not diminish the need in many patients for complex open procedures. These findings should help spur the development of innovative training to maintain the ability to provide these core, specialty-defining procedures safely.PMID:38696840 | DOI:10.1016/j.ygyno.2024.04.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Mitchel Hoffman Victoria Dunsmore William Cliby Dennis Chi Stephanie Wheeler Daniel Clarke-Pearson Source Type: research
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer
CONCLUSIONS: In endometrial cancer, co-mutation of FAT3 and LRP1B not only leads to activation of the immune state, but also represents a subgroup with an improved prognosis, particularly in the MSI-H subtype.PMID:38696842 | DOI:10.1016/j.ygyno.2024.04.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Zhansheng Jiang Mingyu Zhu Lu Zhang Haiyan Cui Richeng Jiang Yanfang Yang Source Type: research
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors
CONCLUSION: Patients with HBOC did not undergo expedited fertility treatment compared to control patients undergoing oocyte and embryo cryopreservation for non-infertility reasons. Patients diagnosed with BRCA1 had more oocytes retrieved compared to the control population which is possibly due to earlier age of presentation in the setting of recommended age of risk reducing surgery being age 35-40. When age matched, cycle outcomes did not differ between HBOC and control patients. Given the known cancer prevention benefit and recommendations for risk-reducing surgery, future studies should focus on guidelines for fertility ...
Source: Gynecologic Oncology - May 2, 2024 Category: Cancer & Oncology Authors: Sharonne Holtzman Lily McCarthy Samantha L Estevez Joseph A Lee Morgan F Baird Dmitry Gounko Alan B Copperman Stephanie V Blank Source Type: research
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment
CONCLUSIONS: EAH patients with MMR-d and p53abn have a significantly higher risk of disease relapse and progression. Thus, MMR-d and p53abn may be used as predictive biomarkers of progestin resistance and endometrial tumorigenesis in EAH.PMID:38691985 | DOI:10.1016/j.ygyno.2024.04.013 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Hongfa Peng Jingjing Jiang Limeng Li Zengfang Hao Hongguang Lian Hui Du Wei Wang Source Type: research
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection
CONCLUSION(S): In this retrospective study of patients with advanced ovarian cancer undergoing CRS with LBR, extended post-operative ABX was not associated with reduced SSI, and prolonged administration of antibiotics should be avoided unless clinically indicated.PMID:38691986 | DOI:10.1016/j.ygyno.2024.04.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Julia Chalif Laura M Chambers Meng Yao Michelle Kuznicki Robert DeBernardo Peter G Rose Chad M Michener Roberto Vargas Source Type: research
"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment
CONCLUSIONS: Patients identified cost, restrictive pharmacy benefits, and initial side effects as barriers to PARP-I usage. Having insurance and a supportive care team were identified as facilitators. Enhancing communication about PARP-I cost and side effects could improve patient experience and receipt of evidence-based maintenance therapy in ovarian cancer.PMID:38691987 | DOI:10.1016/j.ygyno.2024.04.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Anna Jo Bodurtha Smith Caroline O'Brien Ashley Haggerty Emily M Ko Katharine A Rendle Source Type: research
